Skip to main content
Top
Published in: Medical Oncology 9/2014

01-09-2014 | Original Paper

Multi-modality management for loco-regionally advanced laryngeal and hypopharyngeal cancer: balancing the benefit of efficacy and functional preservation

Authors: Wei Qian, Guopei Zhu, Yulong Wang, Xiaoshen Wang, Qinghai Ji, Yu Wang, Shengjin Dou

Published in: Medical Oncology | Issue 9/2014

Login to get access

Abstract

The 5-year overall survival (OS) of loco-regionally advanced laryngeal and hypopharyngeal carcinoma (LA-LHC) has declined over the past two decades following the wide application of non-surgical approaches. We aimed to define the new role of open surgery combined with adjuvant chemoradiotherapy in the treatment of LA-LHC for improving survival while maintaining a functional larynx. In the current study, 90 LA-LHC patients treated with open surgery followed by postoperative RT/CRT in our institute from May 2005 to December 2012 were retrospectively analyzed. OS, disease-free survival (DFS), loco-regional failure-free survival (LRFFS) and distant metastasis-free survival (DMFS) were calculated, and prognostic factors were analyzed. Functional larynx preservation results were evaluated according to the head and neck quality of life (QoL) Scale. With a median follow-up period of 37 months, the 3- and 5-year OS, DFS, LRFFS and DMFS were 71.3, 63.7, 85.9, 73.7 and 55.9, 53.0, 81.6, 71.9 %, respectively. Vascular embolism and extracapsular extension (ECE) of the lymph nodes were prognostic factors for poorer OS (p = 0.045 and 0.046, respectively). Vascular embolism was the only prognostic factor for poorer DMFS (p = 0.005). Patients who underwent a conservative partial laryngectomy (CPL) experienced a higher QoL in the domains of speech, swallowing and emotion. Functional larynx preservation was achieved in 36/45 patients (80 %) who received CPL. The results of our study demonstrated that CPL followed by adequate adjuvant therapy could achieve superior oncological results compared with non-surgical approaches in LA-LHC patients while also maintaining satisfactory functional larynx in a majority of patients.
Literature
1.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRef Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRef
2.
go back to reference Cooper JS, Porter K, Mallin K, et al. National cancer database report on cancer of the head and neck: 10-year update. Head Neck. 2009;31(6):748–58.PubMedCrossRef Cooper JS, Porter K, Mallin K, et al. National cancer database report on cancer of the head and neck: 10-year update. Head Neck. 2009;31(6):748–58.PubMedCrossRef
3.
go back to reference National Comprehensive Cancer Network. Clinical practice guidelines in head and neck cancers. 2014. www.nccn.org. Accessed 30 May 2014. National Comprehensive Cancer Network. Clinical practice guidelines in head and neck cancers. 2014. www.​nccn.​org. Accessed 30 May 2014.
4.
go back to reference The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324(24):1685–90.CrossRef The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324(24):1685–90.CrossRef
5.
go back to reference Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European organization for research and treatment of cancer phase III Trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996;88(13):890–9.PubMedCrossRef Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European organization for research and treatment of cancer phase III Trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996;88(13):890–9.PubMedCrossRef
6.
go back to reference Lefebvre JL, Andry G, Chevalier D, et al. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol. 2012;23(10):2708–14.PubMedCrossRefPubMedCentral Lefebvre JL, Andry G, Chevalier D, et al. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol. 2012;23(10):2708–14.PubMedCrossRefPubMedCentral
7.
go back to reference Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349(22):2091–8.PubMedCrossRef Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349(22):2091–8.PubMedCrossRef
8.
go back to reference Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31(7):845–52.PubMedCrossRefPubMedCentral Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31(7):845–52.PubMedCrossRefPubMedCentral
9.
10.
go back to reference Hoffman HT, Porter K, Karnell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 2006;116111(92):1–13.CrossRef Hoffman HT, Porter K, Karnell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 2006;116111(92):1–13.CrossRef
12.
go back to reference Pfister DG, Laurie SA, Weinstein GS, et al. American society of clinical oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006;24(22):3693–704.PubMedCrossRef Pfister DG, Laurie SA, Weinstein GS, et al. American society of clinical oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006;24(22):3693–704.PubMedCrossRef
13.
go back to reference Richard JM, Sancho-Garnier H, Pessey JJ, et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol. 1998;34(3):224–8.PubMedCrossRef Richard JM, Sancho-Garnier H, Pessey JJ, et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol. 1998;34(3):224–8.PubMedCrossRef
14.
go back to reference Takes RP, Strojan P, Silver CE, et al. Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery. Head Neck. 2012;34(2):270–81.PubMedCrossRef Takes RP, Strojan P, Silver CE, et al. Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery. Head Neck. 2012;34(2):270–81.PubMedCrossRef
15.
go back to reference Wang YL, Feng SH, Zhu J, et al. Impact of lymph node ratio on the survival of patients with hypopharyngeal squamous cell carcinoma: a population-based analysis. PLoS ONE. 2013;8(2):e56613.PubMedCrossRefPubMedCentral Wang YL, Feng SH, Zhu J, et al. Impact of lymph node ratio on the survival of patients with hypopharyngeal squamous cell carcinoma: a population-based analysis. PLoS ONE. 2013;8(2):e56613.PubMedCrossRefPubMedCentral
16.
go back to reference Genden EM, Ferlito A, Rinaldo A, et al. Recent changes in the treatment of patients with advanced laryngeal cancer. Head Neck J Sci Spec. 2008;30(1):103–10.CrossRef Genden EM, Ferlito A, Rinaldo A, et al. Recent changes in the treatment of patients with advanced laryngeal cancer. Head Neck J Sci Spec. 2008;30(1):103–10.CrossRef
17.
go back to reference Terrell JE, Nanavati KA, Esclamado RM, Bishop JK, Bradford CR, Wolf GT. Head and neck cancer-specific quality of life—instrument validation. Arch Otolaryngol. 1997;123(10):1125–32.CrossRef Terrell JE, Nanavati KA, Esclamado RM, Bishop JK, Bradford CR, Wolf GT. Head and neck cancer-specific quality of life—instrument validation. Arch Otolaryngol. 1997;123(10):1125–32.CrossRef
18.
go back to reference Ware JE. SF-36 health survey: manual and interpretation guide, Boston: Health Institute; 1993. Ware JE. SF-36 health survey: manual and interpretation guide, Boston: Health Institute; 1993.
19.
go back to reference Lefebvre JL, Rolland F, Tesselaar M, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer I. 2009;101(3):142–52.CrossRef Lefebvre JL, Rolland F, Tesselaar M, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer I. 2009;101(3):142–52.CrossRef
20.
go back to reference Calais G, Pointreau Y, Alfonsi M, Sire C, Tuchais C, Tortochaux J, Guerif S. Induction chemotherapy for larynx preservation. updated results of the GORTEC 2000-01 randomized trial comparing docetaxel plus cisplatinum plus fluorouracil (TPF) versus cisplatinum plus fluorouracil (PF). EJC Suppl. 2007;5(4):324.CrossRef Calais G, Pointreau Y, Alfonsi M, Sire C, Tuchais C, Tortochaux J, Guerif S. Induction chemotherapy for larynx preservation. updated results of the GORTEC 2000-01 randomized trial comparing docetaxel plus cisplatinum plus fluorouracil (TPF) versus cisplatinum plus fluorouracil (PF). EJC Suppl. 2007;5(4):324.CrossRef
21.
go back to reference Posner MR, Norris CM, Wirth LJ, et al. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol. 2009;20(5):921–7.PubMedCrossRef Posner MR, Norris CM, Wirth LJ, et al. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol. 2009;20(5):921–7.PubMedCrossRef
22.
go back to reference Lefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II Study. J Clin Oncol. 2013;31(7):853–9.PubMedCrossRef Lefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II Study. J Clin Oncol. 2013;31(7):853–9.PubMedCrossRef
23.
go back to reference Dufour X, Hans S, De Mones E, Brasnu D, Menard M, Laccourreye O. Local control after supracricoid partial laryngectomy for “advanced” endolaryngeal squamous cell carcinoma classified as T3. Arch Otolaryngol Head Neck Surg. 2004;130(9):1092–9.PubMedCrossRef Dufour X, Hans S, De Mones E, Brasnu D, Menard M, Laccourreye O. Local control after supracricoid partial laryngectomy for “advanced” endolaryngeal squamous cell carcinoma classified as T3. Arch Otolaryngol Head Neck Surg. 2004;130(9):1092–9.PubMedCrossRef
24.
go back to reference Pinar E, Imre A, Calli C, Oncel S, Katilmis H. Supracricoid partial laryngectomy: analyses of oncologic and functional outcomes. Otolaryngol Head Neck Surg. 2012;147(6):1093–8.PubMedCrossRef Pinar E, Imre A, Calli C, Oncel S, Katilmis H. Supracricoid partial laryngectomy: analyses of oncologic and functional outcomes. Otolaryngol Head Neck Surg. 2012;147(6):1093–8.PubMedCrossRef
25.
go back to reference Laccourreye O, Muscatello L, Laccourreye L, Naudo P, Brasnu D, Weinstein G. Supracricoid partial laryngectomy with cricohyoidoepiglottopexy for “early” glottic carcinoma classified as T1-T2N0 invading the anterior commissure. Am J Otolaryngol. 1997;18(6):385–90.PubMedCrossRef Laccourreye O, Muscatello L, Laccourreye L, Naudo P, Brasnu D, Weinstein G. Supracricoid partial laryngectomy with cricohyoidoepiglottopexy for “early” glottic carcinoma classified as T1-T2N0 invading the anterior commissure. Am J Otolaryngol. 1997;18(6):385–90.PubMedCrossRef
26.
go back to reference Bron L, Brossard E, Monnier P, Pasche P. Supracricoid partial laryngectomy with cricohyoidoepiglottopexy and cricohyoidopexy for glottic and supraglottic carcinomas. Laryngoscope. 2000;110(4):627–34.PubMedCrossRef Bron L, Brossard E, Monnier P, Pasche P. Supracricoid partial laryngectomy with cricohyoidoepiglottopexy and cricohyoidopexy for glottic and supraglottic carcinomas. Laryngoscope. 2000;110(4):627–34.PubMedCrossRef
27.
go back to reference Chevalier D, Laccourreye O, Brasnu D, Laccourreye H, Piquet JJ. Cricohyoidoepiglottopexy for glottic carcinoma with fixation or impaired motion of the true vocal cord: 5-year oncologic results with 112 patients. Ann Otol Rhinol Laryngol. 1997;106(5):364–9.PubMedCrossRef Chevalier D, Laccourreye O, Brasnu D, Laccourreye H, Piquet JJ. Cricohyoidoepiglottopexy for glottic carcinoma with fixation or impaired motion of the true vocal cord: 5-year oncologic results with 112 patients. Ann Otol Rhinol Laryngol. 1997;106(5):364–9.PubMedCrossRef
28.
go back to reference Boscolo-Rizzo P, Maronato F, Marchiori C, Gava A, Da Mosto MC. Long-term quality of life after total laryngectomy and postoperative radiotherapy versus concurrent chemoradiotherapy for laryngeal preservation. Laryngoscope. 2008;118(2):300–6.PubMedCrossRef Boscolo-Rizzo P, Maronato F, Marchiori C, Gava A, Da Mosto MC. Long-term quality of life after total laryngectomy and postoperative radiotherapy versus concurrent chemoradiotherapy for laryngeal preservation. Laryngoscope. 2008;118(2):300–6.PubMedCrossRef
29.
go back to reference Bien S, Okla S, van As-Brooks CJ, Ackerstaff AH. The effect of a heat and moisture exchanger (Provox(A (R)) HME) on pulmonary protection after total laryngectomy: a randomized controlled study. Eur Arch Oto-Rhino-L. 2010;267(3):429–35.CrossRef Bien S, Okla S, van As-Brooks CJ, Ackerstaff AH. The effect of a heat and moisture exchanger (Provox(A (R)) HME) on pulmonary protection after total laryngectomy: a randomized controlled study. Eur Arch Oto-Rhino-L. 2010;267(3):429–35.CrossRef
30.
go back to reference Herranz J, Alvarez Espino M, Ogen Morado C. Pulmonary rehabilitation after total laryngectomy: a randomized cross-over clinical trial comparing two different heat and moisture exchangers (HMEs). Eur Arch Oto Rhino L. 2013; 270(9): 2479–84. Herranz J, Alvarez Espino M, Ogen Morado C. Pulmonary rehabilitation after total laryngectomy: a randomized cross-over clinical trial comparing two different heat and moisture exchangers (HMEs). Eur Arch Oto Rhino L. 2013; 270(9): 2479–84.
31.
go back to reference Wei W, Zhang N. Temporal correlation and multivariate analysis quality of life after laryngectomy. 2011 eleventh international and national head and neck academic conference. Hangzhou, Zhejiang Province, China: 2011:7. Wei W, Zhang N. Temporal correlation and multivariate analysis quality of life after laryngectomy. 2011 eleventh international and national head and neck academic conference. Hangzhou, Zhejiang Province, China: 2011:7.
32.
go back to reference Lefebvre JL, Ang KK. Larynx preservation clinical trial design: key issues and recommendations-A consensus panel summary. Int J Radiat Oncol Biol Phys. 2009;73(5):1293–303.PubMedCrossRef Lefebvre JL, Ang KK. Larynx preservation clinical trial design: key issues and recommendations-A consensus panel summary. Int J Radiat Oncol Biol Phys. 2009;73(5):1293–303.PubMedCrossRef
Metadata
Title
Multi-modality management for loco-regionally advanced laryngeal and hypopharyngeal cancer: balancing the benefit of efficacy and functional preservation
Authors
Wei Qian
Guopei Zhu
Yulong Wang
Xiaoshen Wang
Qinghai Ji
Yu Wang
Shengjin Dou
Publication date
01-09-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 9/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0178-2

Other articles of this Issue 9/2014

Medical Oncology 9/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.